Status:
COMPLETED
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
Lead Sponsor:
Savient Pharmaceuticals
Conditions:
Gout
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous doses of Puricase, administered intravenously, in 40 patients with symptomatic gout. Subjects must wash out...
Eligibility Criteria
Inclusion
- Subjects to be included in the study are:
- Outpatients of either gender, age 18 or older
- Diagnosed with symptomatic gout refractory to conventional therapy or unable to tolerate conventional therapy (for example: having one or more tophi and/or having experienced a gout flare within the previous 6 months and/or having chronic, gouty arthritis)
- Hyperuricemic: screening serum uric acid must be \>=8 mg/dL.
- The patient must be willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed)
- Women of childbearing potential must have a negative serum pregnancy test and must use an approved birth control method during their participation in the protocol. Such methods include oral, injectable, or implantable contraceptives; IUDs and barrier contraceptives in combination with spermicide
Exclusion
- Subjects to be excluded are those for whom any of the following apply:
- Unstable coronary artery disease or uncontrolled hypertension
- History of end stage renal disease requiring dialysis
- History of liver disease, as defined by baseline serum transaminase elevation \>3X the upper limit of normal in the absence of any other known cause
- Organ transplant recipient requiring immunosuppressive therapy
- Concurrent use of prednisone at a dose \>10 mg qd (or equivalent) at or within one week before dosing
- Concurrent use of uric acid-lowering agents
- Prior treatment with Puricase® or other recombinant uricase
- An acute gout flare within one week prior to first treatment with Puricase® (exclusive of chronic synovitis/arthritis) requiring use of medication which violates the protocol
- glucose-6-phosphate dehydrogenase deficiency
- A history of anaphylactic reaction to a recombinant protein or porcine derivatives
- Lactation
- Has taken an investigational drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study
- Known allergy to urate oxidase or PEGylated products
- Has any other medical or psychological condition which, in the opinion of the investigator, might create undue risk to the patient or interfere with the patient's ability to comply with the protocol requirements
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00080210
Start Date
March 1 2004
End Date
February 1 2005
Last Update
June 3 2013
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Spain Rehabilitation Center
Birmingham, Alabama, United States, 35294
2
University of California, San Diego
La Jolla, California, United States, 92037
3
University of Chicago Dept of Medicine
Chicago, Illinois, United States, 60637
4
Graves Gilbert Clinic
Bowling Green, Kentucky, United States, 42101